Why the study?
Does interim PET/CT after one cycle of chemoimmunotherapy predict progression-free survival in patients with newly diagnosed DLBCL?
Does interim PET/CT after one cycle of chemoimmunotherapy predict progression-free survival in patients with newly diagnosed DLBCL?
Interim PET/CT after one cycle of chemoimmunotherapy is not able to safely discriminate PET-positive and PET-negative patients in different prognostic groups for DLBCL.
Answers are grounded in this paper and cite their sources.
Interim PET/CT after one cycle cannot safely discriminate prognostic groups in DLBCL; leaves open its role for early risk stratification.
We evaluated the predictive value of interim positon emission tomography (I-PET) after one course of chemoimmunotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). One hundred and twelve patients with DLBCL were enrolled. All patients had PET/computed tomography (CT) scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International Harmonization Project criteria (IHP), Deauville 5-point scale (D 5PS) with scores 1-3 considered negative (D 5PS > 3) and D 5PS with scores 1-4 considered negative (D 5PS = 5). Ratios of tumor maximum standardized uptake value (SUVmax) to liver SUVmax were also analyzed. We found no difference in progression-free survival (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS > 3. The 2-year PFS using D 5PS = 5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p = 0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET-positive and PET-negative patients in different prognostic groups.
No takes yet. Share an insight, caveat, or question.
Mylam et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: